Editorial: Cancer genome sequencing and potential application in oncology

Future Oncology

Volumn 6, Issue 10, 2010, Pages 1527-1531

  Katsios, Christos ^a   Zoras, Odysseas ^b   Roukos, Dimitrios H ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

biological system; cancer genome sequencing; drug biomarker; genetic interaction; oncology; standard treatment

Indexed keywords

CANCER RISK; CANCER THERAPY; EDITORIAL; GENE SEQUENCE; GENETIC ASSOCIATION; METASTASIS; ONCOLOGY; PRIORITY JOURNAL; DRUG RESISTANCE; GENETICS; GENOMICS; HUMAN; METHODOLOGY; MUTATION; NEOPLASM; RISK FACTOR; STANDARD;

TUMOR MARKER;

DRUG RESISTANCE, NEOPLASM; GENOMICS; HUMANS; MUTATION; NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 78149422807     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.115     Document Type: Editorial

References (33)

1. Donnelly P: Progress and challenges in genome-wide association studies in humans. Nature 456, 728-731 (2008).
2. Easton DF, Eeles RA: Genome-wide association studies in cancer. Hum. Mo l. Genet. 17(R2), R109-R115 (2008).
3. The human genome at ten. Nature 464(7289), 649-650 (2010).
4. Ledford H: Big science: the cancer genome challenge. Nature 464(7291), 972-974 (2010).
5. Check Hayden E: Human genome at ten: life is complicated. Nature 464(7289), 664-667 (2010).
6. Roukos DH: Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3), 283-287 (2010).
7. Schadt EE: Molecular networks as sensors and drivers of common human diseases. Nature 461(7261), 218-223 (2009).
8. Rockman MV: Reverse engineering the genotype-phenotype map with natural genetic variation. Nature 456, 738-744 (2008).
9. Garber AM, Tunis SR: Does comparative-effectiveness research threaten personalized medicine? N. Engl. J. Med. 360(19), 1925-1927 (2009).
10. Stafford RS, Wagner TH, Lavori PW: New, but not improved? Incorporating comparative-effectiveness information into FDA labeling. N. Engl. J. Med. 361(13), 1230-1233 (2009).
11. Roukos DH: Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev. Mol. Diagn. 10(3), 247-250 (2010).
12. Lin K, Lipsitz R, Miller T, Janakiraman S; US Preventive Services Task Force: Benefts and harms of prostate-specifc antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann. Intern. Med. 149(3), 192-199 (2008).
13. Collins F: Has the revolution arrived? Nature 464(7289), 674-675 (2010).
14. Venter JC: Multiple personal genomes await. Nature 464(7289), 676-677 (2010).
15. Katsios C, Roukos DH: Individual genomes and personalized medicine: life diversity and complexity. Per. Med. 7(4), 347-350 (2010).
16. Goldstein DB: 2020 visions: personalized medicine. Nature 463(7277), 26-32 (2010).
17. Kathiresan S, Melander O, Anevski D et al.: Polymorphisms associated with cholesterol and risk of cardiovascular events. N. Engl. J. Med. 358(12), 1240-1249 (2008).
18. Wacholder S, Hartge P, Prentice R et al.: Performance of common genetic variants in breast-cancer risk models. N. Engl. J. Med. 362(11), 986-993 (2010).
19. Roukos DH: Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann. Surg. Oncol. 17, 14-17 (2010).
20. Baselga J, Swain SM: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9(7), 463-475 (2009).
21. Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S: Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 13(6), 620-630 (2008).
22. Van Cutsem E, Köhne CH, Hitre E et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408-1417 (2009).
23. Linardou H, Dahabreh IJ, Kanaloupiti D et al.: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9(10), 962-972 (2008).
24. Stratton MR, Campbell PJ, Futreal PA: The cancer genome. Nature 458(7239), 719-724 (2009).
25. Friedman A, Perrimon N: Genetic screening for signal transduction in the era of network biology. Cell 128, 225-231 (2007).
26. Roukos DH: Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev. Mol. Diagn. 10(1), 33-48 (2010).
27. Roukos DH: Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8), 1039-1043 (2010).
28. Roukos DH, Katsios C, Liakakos T: Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev. Mol. Diagn. 10(5), 541-545 (2010).
29. Roukos DH, Ziogas DE, Katsios C: Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks. Expert Rev. Anticancer Ther. 10(8), 1187-1195 (2010).
30. Roukos DH, Ziogas D: From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev. Anticancer Ther. 10(2), 123-128 (2010).
31. Roukos DH: Isolated tumor cells in breast cancer. N. Engl. J. Med. 361, 1994-1995 (2009).
32. Roukos DH. Tzakos A, Zografos G: Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev. Anticancer Ther. 9(10), 1413-1416 (2009).
33. Ziogas D, Roukos DH: Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann. Surg. Oncol. 16(7), 1771-1782 (2009).